|
US2009191138A1
|
|
Novel topical formulations for improving the appearance of nails
|
|
AU2005333545A1
|
|
Hydrophobic polyamine amides as potent lipopolysaccharide sequestrants
|
|
US2006078580A1
|
|
Organo-gel formulations for therapeutic applications
|
|
US2005245615A1
|
|
Composition containing polyamine transport inhibitor and use thereof
|
|
US2006078577A1
|
|
Organo-gel formulations for therapeutic applications
|
|
WO2005105729A1
|
|
Polyamine analogs that activate antizyme frameshifting
|
|
US2004209926A1
|
|
Polyamine analogs that activate antizyme frameshifting
|
|
US2005209264A1
|
|
Tetrahydro-β-carboline compounds and use thereof
|
|
EP1813636A1
|
|
Polyamine analogs that activate antizyme frameshifting
|
|
WO03105779A2
|
|
Guanidine compounds as anesthetics and for treatment of nervous system disorders
|
|
US6919483B2
|
|
Immunomodulation with novel pharmaceutical compositions
|
|
AU2003200048B2
|
|
Novel polyamine analogues as therapeutic and diagnostic agents
|
|
CA2471953A1
|
|
Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners
|
|
US2004058954A1
|
|
Polyamine analogs that activate antizyme frameshifting
|
|
US6872852B2
|
|
Polyamine analogues as cytotoxic agents
|
|
EP1857109A2
|
|
Inhibitors of melanocyte tyrosinase as topical skin lighteners
|
|
US7208528B1
|
|
Polyamine analogues as therapeutic and diagnostic agents
|
|
AU8496898A
|
|
Novel polyamine analogues as therapeutic and diagnostic agents
|
|
EP1867633A1
|
|
Polyamine analogues as therapeutic and diagnostic agents
|
